The Next Frontier for Menin Inhibitors in AML

In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed how menin inhibitors are poised to play an increasingly important role in the treatment of acute myeloid leukemia (AML) as precision medicine continues to reshape clinical practice.

Wang explains that the clinical impact of menin inhibition extends beyond NPM1-mutated AML, highlighting the activity of this therapeutic class in AML with KMT2A or MLL rearrangements. She notes that the success of both ziftomenib (Komzifti) and revumenib (Revuforj) across these molecularly defined subtypes underscores the growing importance of menin inhibitors as a foundational targeted therapy in AML. As additional data emerge, she expects these agents to move earlier in the treatment paradigm and become part of standard therapy for a broader population of patients. As such, she stresses that comprehensive molecular profiling at diagnosis and relapse is essential to identify actionable genomic alterations and match patients with the most appropriate targeted therapies.

Looking ahead, Wang discusses how oral targeted agents such as ziftomenib may improve outcomes without substantially increasing treatment-related toxicity, making them especially attractive for the predominantly older AML population. As the incidence of secondary AML continues to rise and therapeutic options expand, she concludes that menin inhibitors represent an important advance toward more effective, biology-driven treatment strategies that have the potential to further improve long-term survival.